Richard Adcock
Chief Executive Officer, ImmunityBio
Professional Overview
Richard Adcock is a seasoned healthcare executive with over 25 years of experience driving innovation and operational excellence across the industry. As the Chief Executive Officer of ImmunityBio, he oversees the strategic direction and day-to-day operations of the pioneering immunotherapy company, leading its mission to transform the treatment of cancer and infectious diseases.
Experience Summary
Current Role
As CEO of ImmunityBio since 2020, Richard has spearheaded the company's efforts to develop next-generation immunotherapies and accelerate the advancement of its robust clinical pipeline. Under his leadership, ImmunityBio has made significant strides in expanding its research and development capabilities, forging strategic partnerships, and positioning the company as a leader in the field of cellular and molecular immunology.
Career Progression
Prior to joining ImmunityBio, Richard served as the Chief Executive Officer of Verity Health System, where he led the turnaround and operational optimization of the multi-hospital system. He has also held senior leadership roles at Sanford Health, including Chief Innovation Officer and President, during which he drove the implementation of cutting-edge technologies and pioneered new models of care delivery.
Earlier in his career, Richard held engineering and research and development positions at GE Healthcare and Micro Medical Systems, Inc., where he contributed to the development of innovative medical devices and technologies.
Academic Background
Richard holds a Bachelor of Science degree in Mechanical Engineering from the University of South Dakota, where he graduated with distinction.
Areas of Expertise
- Healthcare administration and operations
- Strategic planning and organizational transformation
- Innovation and technology implementation
- Immunotherapy and oncology drug development
- Regulatory compliance and quality assurance
Professional Impact
Under Richard's leadership, ImmunityBio has made significant advancements in its clinical pipeline, including the ongoing development of its novel N-803 immunotherapy for the treatment of various cancers. Additionally, he has been instrumental in forging strategic partnerships with leading academic and industry organizations to accelerate the company's research and development efforts.
Conclusion
With his extensive healthcare experience, deep technical expertise, and proven track record of driving transformative change, Richard Adcock is well-positioned to lead ImmunityBio in its mission to develop innovative immunotherapies that have the potential to revolutionize the treatment of cancer and infectious diseases.
